Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Vistagen logo — Changing the trajectory of mental health care – One Mind at...

Vistagen

Changing the trajectory of mental health care – One Mind at a Time

Founded 1998 United States South San Francisco, United States 58 employees Post Ipo Equity Total: $154.75M Biotechnology, Pharmaceutical

General Information

Company Name Vistagen
Founded Year 1998
Location United States South San Francisco, United States +1
Founders / Decision Makers
Team member
Employees 58
Industries Biotechnology, Pharmaceutical
Funding Stage Post Ipo Equity
Social

Get notified when Vistagen moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Vistagen

Vistagen is a late clinical-stage biopharmaceutical company, traded on Nasdaq under the ticker symbol VTGN, that is revolutionizing mental health care with its pioneering neuroscience approach. The company's focus is on developing first-in-class therapies for psychiatric and neurological disorders. Vistagen has six clinical-stage product candidates, five of which belong to a new class of drugs known as pherines - fasedienol (PH94B), itruvone (PH10), PH80, PH15, and PH284. These investigational neuroactive nasal sprays have innovative proposed mechanisms of action, activating chemosensory neurons in the nasal passages to impact neural circuits in the brain without systemic absorption or receptor binding. Additionally, Vistagen’s sixth clinical-stage product candidate, AV-101, is an investigational oral drug candidate with the potential to inhibit NMDA receptor activity. Founded in 1998, Vistagen operates in the biotechnology and pharmaceutical industries, with its headquarters in the United States. The company recently secured a significant investment of $100.00M in post-IPO equity from a consortium of notable investors including BVF Partners, Commodore Capital, Logos Capital, Nantahala Capital, TCG Crossover, Great Point Partners, and Surveyor Capital on 02 October 2023. With its focus on transforming the treatment of anxiety, depression, and other neuroscience disorders, Vistagen stands at the forefront of innovative, potentially game-changing therapies for mental health.

Taxonomy: biopharmaceutical company, neuroscience, clinical-stage product candidates, psychiatric disorders, neurological disorders, pherines, neuroactive nasal sprays, NMDA receptor activity, AV-101, central nervous system, MDD, drug development, mental health, innovation, therapy

Funding Rounds & Investors (8)

View All
Funding Stage Amount Investors Lead Investors Date
Post-IPO Equity •••••• 7
Investor Investor Investor Investor Investor
•••• •••• 		02 Oct 2023
Post-IPO Equity •••••• - 02 Jun 2016
Post-IPO Equity •••••• - 06 Aug 2015
Post-IPO Equity •••••• - 02 Jul 2014
Post-IPO Equity •••••• - 10 Apr 2013

View All 8 Funding Rounds

Vistagen Alternatives & Competitors

Vistagen vs
Brain & Behavior Research Foundation (BBRF)
Brain & Behavior Research Foundation (BBRF) United States

100% of every dollar donated for research is invested in our mental health research grants.

38 employees
Health Care
Compare Vistagen vs Brain & Behavior Research Foundation (BBRF)
Vistagen vs
Neumora
Neumora United States

Pioneering a new era of medicines for brain diseases

Series B
111 employees
Biotechnology, Health Care
Compare Vistagen vs Neumora
Vistagen vs
Arcade Therapeutics
Arcade Therapeutics United States

We make therapeutic games for mental well-being, supported by rigorous evidence.

Seed
10 employees
Digital Health, Health Care
Compare Vistagen vs Arcade Therapeutics

FAQ About Vistagen

Changing the trajectory of mental health care – One Mind at a Time
Vistagen was founded in 1998.
Vistagen is headquartered in South San Francisco, United States.
Vistagen operates in the following industries: Biotechnology, Pharmaceutical.
Vistagen has approximately 58 employees.
Vistagen has completed 8 funding rounds, raising a total of $154.75M. The latest funding stage is Post Ipo Equity.
Top alternatives and competitors to Vistagen include Brain & Behavior Research Foundation (BBRF), Neumora, Arcade Therapeutics, Amsterdam UMC - Amsterdam Neuroscience, Pacific Neuroscience Institute (PNI). These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Vistagen and Brain & Behavior Research Foundation (BBRF) are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Vistagen and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy

Book a demo 30 minutes